Abstract
Background: Tamoxifen is an estrogen antagonist used as neo-adjuvant drug for breast cancer treatment in women.
Objective: To evaluate tamoxifen monotherapy on breast cancer for elderly women with estrogen positive, progesterone
positive, and Her2/neu negative.
Materials and methods: Seventeen breast cancer women were examined. The age range of the patients was between
73 and 87 years (mean SD: 79.2 3.8 years). The patients were examined and diagnosed by a surgeon, and
histopathologic examination. The patients included in the study were estrogen positive, progesterone positive, and
Her2/neu negative. The patients were treated with tamoxifen monotherapy 20 mg/day orally during the two-year
study. The size of the tumor were measured by ultrasonic examination for each patient. Five milliliters (mL) of blood
samples were taken from the patients and analyzed for CA15-3. The clinical and ultrasonic examination as well as blood
investigations were carried out every 3 months for two years, while only clinical examinations were continued every six
months up to 5 years.
Results: Treatment of breast cancer women by tamoxifen 20 mg/day gradually decreased serum CA15-3 signicantly
(p 0.01) every 3 months. After two years of treatment with tamoxifen, serum CA15-3 was within normal range. The
size of the tumor was decreased signicantly and gradually every 3 months. After two years the tumor was completely
disappeared. Each parameter was compared with that parameter measured before 3 months. Lymph node positive
patients were 11 out of 17 patients; however, after 21 months of tamoxifen treatment, all patients were lymph node
negative.
Conclusion: Tamoxifen monotherapy can be used for the treatment of women with breast cancer with estrogen +,
progesterone + and Her2/neu–. The program can be applied for elderly breast cancer women or incompliance patients.
Objective: To evaluate tamoxifen monotherapy on breast cancer for elderly women with estrogen positive, progesterone
positive, and Her2/neu negative.
Materials and methods: Seventeen breast cancer women were examined. The age range of the patients was between
73 and 87 years (mean SD: 79.2 3.8 years). The patients were examined and diagnosed by a surgeon, and
histopathologic examination. The patients included in the study were estrogen positive, progesterone positive, and
Her2/neu negative. The patients were treated with tamoxifen monotherapy 20 mg/day orally during the two-year
study. The size of the tumor were measured by ultrasonic examination for each patient. Five milliliters (mL) of blood
samples were taken from the patients and analyzed for CA15-3. The clinical and ultrasonic examination as well as blood
investigations were carried out every 3 months for two years, while only clinical examinations were continued every six
months up to 5 years.
Results: Treatment of breast cancer women by tamoxifen 20 mg/day gradually decreased serum CA15-3 signicantly
(p 0.01) every 3 months. After two years of treatment with tamoxifen, serum CA15-3 was within normal range. The
size of the tumor was decreased signicantly and gradually every 3 months. After two years the tumor was completely
disappeared. Each parameter was compared with that parameter measured before 3 months. Lymph node positive
patients were 11 out of 17 patients; however, after 21 months of tamoxifen treatment, all patients were lymph node
negative.
Conclusion: Tamoxifen monotherapy can be used for the treatment of women with breast cancer with estrogen +,
progesterone + and Her2/neu–. The program can be applied for elderly breast cancer women or incompliance patients.
Keywords
Breast Cancer
Estrogen(+)
Her2/neu(-)
Progesterone(+)
Serum CA15-3
tamoxifen